Medindia LOGIN REGISTER
Medindia
Advertisement

Derma Sciences Raises $6.1 Million Through Private Placement

Wednesday, April 2, 2008 General News
Advertisement
PRINCETON, N.J., April 1, 2008 Derma SciencesInc (OTC Bulletin Board: DSCI), a provider of advanced wound care products,said that its MEDIHONEY(TM) Wound & Burn Dressing with Active LeptospermumHoney has been well received by its target audience, and the Company believesstrongly in the potential that it offers for rewarding growth. As a result,the Company intends to accelerate the expansion of its sales force and tobroaden the scope of its licensing agreement with Comvita New Zealand, Ltd,its commercialization partner for MEDIHONEY. To facilitate this, the Companyentered into securities purchase agreements with several accredited existingand new investors in connection with a private placement of common stock andwarrants. Under the terms of the agreement, Derma will receive $6.1 million ingross proceeds from the sale of 6.1 million shares of its common stock andapproximately 3.1 million warrants with an exercise price of $1.20. Subject tothe satisfaction of customary closing conditions, the transaction is expectedto close on or about April 2, 2008.
Advertisement

Aside from the sales force expansion and potentially a broadened licenseagreement relating to MEDIHONEY, net proceeds from the transaction will bealso used for working capital as well as for general corporate purposes.Pending such uses, the proceeds are expected to temporarily pay down theCompany's existing revolving credit facility. The offering was conducted inreliance on Section 4(2) of the Securities Act of 1933, as amended, and Rule506 promulgated there under.
Advertisement

Chairman and CEO Ed Quilty commented, "MEDIHONEY has the potential toimprove the quality of life for people with hard-to-heal wounds that are aresult of diabetes, vascular insufficiencies, and pressure ulcers -- the baneof nursing home patients. We also believe it will play an important rolearound the globe as clinicians look for more effective and less toxic ways todeal with the onslaught of 'superbugs' such as MRSA. The proceeds from thisprivate placement will help ensure that we achieve our key strategicinitiatives -- to expand our sales force more rapidly and to maximize ourgrowing success with the MEDIHONEY brand."

The private placement is set to fund on April 2, 2008. Quilty emphasizedthat the Company continues to self-fund its research and product developmentcosts on all other products in its product line, and does not anticipate afurther need for finances beyond this one-time push for MEDIHONEY. "The timeis right for MEDIHONEY," he said, "and we decided not to wait."

The Company plans to announce results for its 4th quarter and year endedDecember 31, 2007, this morning as well.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world byDerma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for themanagement of wounds and burns. The product has been shown to be effective ina variety of wounds and burns, and was recently the focus of two positivelarge-scale randomized controlled studies on leg ulcers. For more informationabout Derma Sciences, Inc., visit its home page on the Internet athttp://www.dermasciences.com.

Forward-looking Statements

Statements contained in this release that are not statements of historicalfact may be deemed to be forward-looking statements. Without limiting thegenerality of the foregoing, words such as "may," "will," "expect," "believe,""anticipate," "intend," "could," "estimate" or "continue" are intended toidentify forward-looking statements. Readers are cautioned that certainimportant factors may affect the Company's actual results and could cause suchresults to differ materially from any forward-looking statements which may bemade in this release or which are other
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close